welcome

...to our new-look newsletter! We hope you find this new format gives you a better overview of our recent news. This edition features a report from our recent Governing Board meeting and clinical trials planning workshop, plus three NMD-focussed research funding opportunities.

Please forward any items that you would like to be included in future editions to info@treat-nmd.eu.

Best wishes,
The TREAT-NMD coordination team

at a glance...

Meetings & Events

12-14 Sep 2008 EAMDA/TREAT-NMD conference
03-04 Oct 2008 European Research Conference in Paediatric Neurology
02-04 Feb 2009 TREAT-NMD Governing Board and Science and Technology Advisory Council Meetings
09-12 Sep 2009 IDMC-7 International Myotonic Dystrophy Consortium

TREAT-NMD host workshop on clinical trials in neuromuscular disease

From 19th – 21st June the Clinical Trials Coordination Centre of TREAT-NMD organized its first Workshop on “Clinical Trials in Neuromuscular Diseases” in Freiburg, Germany. During the course, participants from 8 countries learned how to successfully organise a clinical trial.

MORE >

TREAT-NMD’s third Governing Board meeting

TREAT-NMD held its third Governing Board meeting in Newcastle in the last week of June. Click "more" to read about the network’s latest news in our meeting report.

MORE >

SMA Europe research funding opportunity

SMA Europe has launched an 80,000 EUR Call for Proposals, open to any research project which aims to find a cure or therapy for Spinal Muscular Atrophy (SMA). The application deadline is 26th August 2008.

MORE >

Duchenne Ireland research funding opportunity

Duchenne Ireland has released details of a €200,000 funding opportunity for research projects aimed at finding a treatment or potential cure for Duchenne Muscular Dystrophy.

MORE >
<table>
<thead>
<tr>
<th>International Myotonic Dystrophy Consortium Congress</th>
<th>European multidisciplinary approaches to rare disease research</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 years after the first description of myotonic dystrophy by Hans Steinert (Leipzig, Germany), the International Myotonic Dystrophy Consortium’s biannual congress is taking place in the city of Würzburg in September 2009.</td>
<td>A session dedicated to research on rare diseases, organised by the European Commission, took place in Paris on 6 June during the Salon Européen de la Recherche et de l’Innovation, which highlighted the value added by European multidisciplinary approaches. Dr. Stefanie Possekel (Santhera Pharmaceuticals Ltd) illustrated the attractiveness of research on orphan drugs for industry and the need to establish effective partnership with academia, clinicians and patient organisations.</td>
</tr>
</tbody>
</table>

**MORE >**

<table>
<thead>
<tr>
<th>ICE and TREAT-NMD collaborate</th>
<th>Muscular Dystrophy Ireland research funding opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Researchers, clinicians, and patient associations from different countries have joined forces to develop measures to enable clinical trials using exon skipping as quickly as possible.</td>
<td>Muscular Dystrophy Ireland is inviting researchers to make an application for funding. Applications for research that may contribute to potential treatments for muscular dystrophy will be especially welcomed.</td>
</tr>
</tbody>
</table>

**MORE >**